Navigation Links
VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
Date:1/28/2010

BEDFORD, Mass., Jan. 28 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that it has acquired the fluorescence imaging agent intellectual property portfolios and related technology platforms from Bayer Schering Pharma AG, Germany.  The patent acquisition includes over 45 issued patents worldwide covering a wide range of fluorescence agent constructs and imaging methods, and consolidates VisEn's patent and technology leadership position in the emerging markets of fluorescence imaging from preclinical research through clinical molecular diagnostics.

"We have closely tracked the very high quality of Bayer Schering Pharma's fluorescence agent technologies and extensive patent portfolios over the last decade, and we are pleased to now integrate these platforms into VisEn's programs," said Kirtland Poss, President and CEO of VisEn Medical.  "The acquisition of these assets significantly expands VisEn's patent coverage of in vivo fluorescent imaging agents, and adds to our R&D capability and pipeline of preclinical agent products and clinical imaging agents going forward."

With this acquisition, VisEn's intellectual property portfolio covering fluorescence imaging agents now includes over 150 patents and patent applications worldwide.  The collective patent estate provides comprehensive coverage of a broad range of core agent components and chemistries, as well as key preclinical and clinical applications and methods.  Included in the acquired portfolio are key patents covering physiologic agents, bioconjugates and targeted fluorescence agents, and certain activatable imaging agents for measurement of diverse biomarker activity in living systems.  With the addition of these new platforms, VisEn plans to further expand the aggressive development of its preclinical agent product offerings, as well as its clinical imaging agent pipeline and related programs.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT™) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.  The Company also works with large pharmaceutical companies and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical research and clinical program areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.

RELATED LINKS
http://www.visenmedical.com

'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
4. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
5. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
8. U.S. Preventive Medicine Acquires Specialty Disease Management
9. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
10. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
11. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/8/2017)... , May 8, 2017  Diplomat Pharmacy, Inc. ... Communications, Inc. ("WRB"), a health care service center ... WRB specializes in relationship management programs for ... WRB will join ... commercialization support services for manufacturers, biotech firms, and other ...
(Date:5/6/2017)... 5, 2017  May is Stroke Awareness Month and ... most important methods to prevent a stroke: monitor and ... Disease Control and Prevention, undetected and uncontrolled hypertension is ... the global leader in personal heart health technology, recently ... heart attack and stroke and is advancing a national ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... ... From May 21-23, hearing healthcare professionals gained a competitive edge with training ... Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s technology partner, Oticon ... to help them stay ahead in the industry. At the event, EarQ members learned ...
(Date:5/26/2017)... , ... May 26, 2017 , ... ... announce a new educational seminar to focus on current legislative activity and the ... will begin at 1 p.m. Sunday, Sept. 10, and will continue through Monday, ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical areas. ... “We are thrilled to partner with Cupron® to provide customers with a game ...
(Date:5/26/2017)... ... 2017 , ... Rob Lowe acts as host and helps educate and inform ... hiking in American. Viewers can reconnect with America as it explores some of the ... consumers have looked for an inventive new place for a family vacation, and have ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: retells ... Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, horse farmer, ... moved to NYC when she was three. At six, they moved to Dayton, Ohio, ...
Breaking Medicine News(10 mins):